Resverlogix Company Description

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses.

The company’s lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions.

It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.

Resverlogix Corp.

Country	Canada
Industry	Biological Products, Except Diagnostic Substances
Employees	19
CEO	Donald McCaffrey

Contact Details

Address: 4820 Richard Road SW Calgary, AB T3E 6L1 Canada
Phone	403 254 9252
Website	resverlogix.com

Stock Details

Ticker Symbol	RFS
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Donald McCaffrey	Chief Executive Officer
Aaron Cann	Chief Financial Officer